GDX vs XBI
VanEck Gold Miners ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.51% for GDX.
- • GDX pays a higher dividend yield (0.84%).
Side-by-side metrics
| Metric | GDX | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.51% | 0.35% |
Dividend yield Trailing 12-month yield. | 0.84% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $22.75B | $10.73B |
YTD return | -14.27% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.81 | 1.10 |
P/E ratio | 13.69 | — |
Last price | $76.00 | $164.01 |
Inception | — | — |
Issuer | VanEck | State Street |
GDX top holdings
| AEM.TO | Agnico Eagle Mines Ltd | 10.52% |
| NEM | Newmont Corp | 10.48% |
| ABX.TO | Barrick Mining Corp | 7.95% |
| WPM.TO | Wheaton Precious Metals Corp | 5.51% |
| AU | Anglogold Ashanti PLC | 5.07% |
| FNV.TO | Franco-Nevada Corp | 4.84% |
| K.TO | Kinross Gold Corp | 4.40% |
| GFI | Gold Fields Ltd ADR | 4.01% |
| PAAS.TO | Pan American Silver Corp | 2.95% |
| NST.AX | Northern Star Resources Ltd | 2.70% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About GDX
GDX (VanEck Gold Miners ETF) is Major gold mining companies. Managed by VanEck, the fund carries $22.8B in assets under management, an expense ratio of 0.51%, a dividend yield of 0.84%. Its largest holding is Agnico Eagle Mines Ltd (AEM.TO), which represents 10.5% of the portfolio. Basic Materials is the fund's largest sector exposure at 100.0%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.